Publications by authors named "D G Bebb"
Article Synopsis
- - This study examines treatment patterns and real-world overall survival (rwOS) in patients with extensive-stage small cell lung cancer (ES-SCLC) after the introduction of anti-PD-L1 therapies in 2019 and 2020.
- - Researchers analyzed a nationwide database, focusing on patients who received systemic therapy from 2013 to 2021, finding that etoposide plus platinum chemotherapy was the most common first-line treatment.
- - Despite the use of anti-PD-L1 therapies, the median overall survival rates for patients were relatively low: 8.3 months for those treated with 1L anti-PD-L1 compared to 8.0 months for those who were not, indicating ongoing challenges
Introduction: The treatment landscape of small cell lung cancer (SCLC) is evolving. Evidence generated from administrative claims is needed to characterize real-world SCLC patients. However, the current ICD-10 coding system cannot distinguish SCLC from non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates treatment patterns and outcomes for real-world SCLC patients in the US who underwent three or more lines of therapy, highlighting the complexities of their care.
- It analyzed a group of 326 patients, revealing median overall survival of 5.3 months and a progression-free survival of 2.5 months after receiving three lines of treatment.
- The findings emphasize the poor efficacy of current therapies for advanced SCLC and highlight the urgent need for new treatment options.
Introduction: Understanding of the patient-perceived symptom burden of small cell lung cancer (SCLC) is limited. The objective of this study was to explore patients' experiences with SCLC, identify which treatment-/disease-related symptoms have the greatest impact on their well-being, and gain caregiver perspectives.
Methods: A noninterventional, cross-sectional, multimodal, mixed methods study was conducted from April-June 2021.
The use, safety and effectiveness of crizotinib as part of the management of ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this retrospective review. Twenty-one ROS1-rearranged patients with advanced/metastatic disease receiving crizotinib between 2014-2020 were identified; crizotinib demonstrated tolerability and effectiveness in this population where outcomes were similar to those described in other crizotinib-treated real-world cohorts, but lower than those of the PROFILE 1001 clinical trial population. Systemic anti-cancer therapy prior to crizotinib initiation occurred in half of the study cohort, with platin-pemetrexed and immune checkpoint inhibitors being most common.
View Article and Find Full Text PDF